
Pascal M. Bui Pho
Examiner (ID: 9276)
| Most Active Art Unit | 2878 |
| Art Unit(s) | 3793, 3741, 3737, 3798, 2878 |
| Total Applications | 629 |
| Issued Applications | 416 |
| Pending Applications | 21 |
| Abandoned Applications | 193 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17665277
[patent_doc_number] => 11358958
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-06-14
[patent_title] => Inhibitors of cyclin-dependent kinases
[patent_app_type] => utility
[patent_app_number] => 17/095672
[patent_app_country] => US
[patent_app_date] => 2020-11-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 56992
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 151
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17095672
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/095672 | Inhibitors of cyclin-dependent kinases | Nov 10, 2020 | Issued |
Array
(
[id] => 17875510
[patent_doc_number] => 11447511
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-20
[patent_title] => Dioxolane analogues of uridine for the treatment of cancer
[patent_app_type] => utility
[patent_app_number] => 17/087483
[patent_app_country] => US
[patent_app_date] => 2020-11-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19250
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 115
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17087483
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/087483 | Dioxolane analogues of uridine for the treatment of cancer | Nov 1, 2020 | Issued |
Array
(
[id] => 16839380
[patent_doc_number] => 20210147392
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-20
[patent_title] => SYNTHESIS OF CERDULATINIB
[patent_app_type] => utility
[patent_app_number] => 17/076356
[patent_app_country] => US
[patent_app_date] => 2020-10-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9185
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17076356
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/076356 | Synthesis of cerdulatinib | Oct 20, 2020 | Issued |
Array
(
[id] => 17044927
[patent_doc_number] => 11098095
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2021-08-24
[patent_title] => Methods of inhibiting MMP-9
[patent_app_type] => utility
[patent_app_number] => 17/073620
[patent_app_country] => US
[patent_app_date] => 2020-10-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 7
[patent_no_of_words] => 2473
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17073620
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/073620 | Methods of inhibiting MMP-9 | Oct 18, 2020 | Issued |
Array
(
[id] => 16893172
[patent_doc_number] => 11034705
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-06-15
[patent_title] => Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/074337
[patent_app_country] => US
[patent_app_date] => 2020-10-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36715
[patent_no_of_claims] => 58
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 210
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17074337
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/074337 | Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors | Oct 18, 2020 | Issued |
Array
(
[id] => 16570525
[patent_doc_number] => 20210009531
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-14
[patent_title] => DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS
[patent_app_type] => utility
[patent_app_number] => 17/032486
[patent_app_country] => US
[patent_app_date] => 2020-09-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35693
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 213
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17032486
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/032486 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | Sep 24, 2020 | Abandoned |
Array
(
[id] => 18101183
[patent_doc_number] => 11541052
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-01-03
[patent_title] => Compounds
[patent_app_type] => utility
[patent_app_number] => 17/030268
[patent_app_country] => US
[patent_app_date] => 2020-09-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 18932
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 148
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17030268
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/030268 | Compounds | Sep 22, 2020 | Issued |
Array
(
[id] => 16777989
[patent_doc_number] => 20210115066
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-22
[patent_title] => DITHIO ETP DERIVATIVES
[patent_app_type] => utility
[patent_app_number] => 17/030073
[patent_app_country] => US
[patent_app_date] => 2020-09-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 58806
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17030073
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/030073 | Dithio ETP derivatives | Sep 22, 2020 | Issued |
Array
(
[id] => 17299382
[patent_doc_number] => 20210395221
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-23
[patent_title] => THERAPEUTIC INHIBITORY COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 17/027637
[patent_app_country] => US
[patent_app_date] => 2020-09-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 66770
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17027637
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/027637 | THERAPEUTIC INHIBITORY COMPOUNDS | Sep 20, 2020 | Abandoned |
Array
(
[id] => 16915784
[patent_doc_number] => 20210188876
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-24
[patent_title] => FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATE INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/025790
[patent_app_country] => US
[patent_app_date] => 2020-09-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36601
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17025790
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/025790 | Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors | Sep 17, 2020 | Issued |
Array
(
[id] => 17997813
[patent_doc_number] => 11498907
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-15
[patent_title] => Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof
[patent_app_type] => utility
[patent_app_number] => 17/015450
[patent_app_country] => US
[patent_app_date] => 2020-09-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 8926
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 80
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17015450
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/015450 | Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof | Sep 8, 2020 | Issued |
Array
(
[id] => 17814284
[patent_doc_number] => 11419871
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-08-23
[patent_title] => Therapeutic agent for lung cancer that has acquired EGFR-TKI resistance
[patent_app_type] => utility
[patent_app_number] => 17/014011
[patent_app_country] => US
[patent_app_date] => 2020-09-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 59
[patent_no_of_words] => 11598
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17014011
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/014011 | Therapeutic agent for lung cancer that has acquired EGFR-TKI resistance | Sep 7, 2020 | Issued |
Array
(
[id] => 17540989
[patent_doc_number] => 11306099
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2022-04-19
[patent_title] => Compounds and methods for modulating Bruton's Tyrosine Kinase
[patent_app_type] => utility
[patent_app_number] => 17/004943
[patent_app_country] => US
[patent_app_date] => 2020-08-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 96461
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 466
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17004943
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/004943 | Compounds and methods for modulating Bruton's Tyrosine Kinase | Aug 26, 2020 | Issued |
Array
(
[id] => 16483881
[patent_doc_number] => 20200377482
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-03
[patent_title] => SUBSTITUTED 3-AZABICYCLO[3.1.0]HEXANES AS KETOHEXOKINASE INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 16/999295
[patent_app_country] => US
[patent_app_date] => 2020-08-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28795
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16999295
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/999295 | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors | Aug 20, 2020 | Issued |
Array
(
[id] => 16468144
[patent_doc_number] => 20200369681
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-26
[patent_title] => PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 16/947651
[patent_app_country] => US
[patent_app_date] => 2020-08-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11902
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -1
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16947651
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/947651 | Pyrimidine compounds and pyrimido indole compounds and methods of use | Aug 10, 2020 | Issued |
Array
(
[id] => 16842840
[patent_doc_number] => 11014913
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-05-25
[patent_title] => Pyridazinones as PARP7 inhibitors
[patent_app_type] => utility
[patent_app_number] => 16/990677
[patent_app_country] => US
[patent_app_date] => 2020-08-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 17
[patent_no_of_words] => 145602
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16990677
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/990677 | Pyridazinones as PARP7 inhibitors | Aug 10, 2020 | Issued |
Array
(
[id] => 16468143
[patent_doc_number] => 20200369680
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-26
[patent_title] => PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 16/947650
[patent_app_country] => US
[patent_app_date] => 2020-08-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11900
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -1
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16947650
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/947650 | Pyrimidine compounds and pyrimido indole compounds and methods of use | Aug 10, 2020 | Issued |
Array
(
[id] => 16468150
[patent_doc_number] => 20200369687
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-26
[patent_title] => Process for Preparing a Triazine-Based Precursor, the Precursor Prepared Thereby, a Method for Producing a Micro-Particulate Complex Using the Precursor, and the Micro-Particulate Complex Produced Thereby
[patent_app_type] => utility
[patent_app_number] => 16/988775
[patent_app_country] => US
[patent_app_date] => 2020-08-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5663
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -1
[patent_words_short_claim] => 132
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16988775
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/988775 | Process for preparing a triazine-based precursor, the precursor prepared thereby, a method for producing a micro-particulate complex using the precursor, and the micro-particulate complex produced thereby | Aug 9, 2020 | Issued |
Array
(
[id] => 17554863
[patent_doc_number] => 11311520
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-04-26
[patent_title] => Substituted dihydroimidazopyridinediones as MKNK1 and MKNK2 inhibitors
[patent_app_type] => utility
[patent_app_number] => 16/983768
[patent_app_country] => US
[patent_app_date] => 2020-08-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 55809
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 5
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16983768
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/983768 | Substituted dihydroimidazopyridinediones as MKNK1 and MKNK2 inhibitors | Aug 2, 2020 | Issued |
Array
(
[id] => 16435626
[patent_doc_number] => 20200352951
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-12
[patent_title] => THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/940542
[patent_app_country] => US
[patent_app_date] => 2020-07-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32238
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 128
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16940542
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/940542 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF USE THEREOF | Jul 27, 2020 | Abandoned |